Indeed, it has been shown that low expression of MEG3 correlates with short survival in GBM patients and, if reintroduced in glioma stem cells (GSCs), it inhibits cell proliferation and in vivo tumor growth [42]. This evidence concerns the gene MEG3 and central nervous system cancer.